PRKAG2

Across TCGA pan-cancer cohorts, PRKAG2 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of PRKAG2’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where PRKAG2 RNA is repressed in tumor relative to normal tissue. In most cancer types PRKAG2 is over-expressed in tumor, although a few such as THCA and BLCA show the opposite, repressed pattern.

THCA, BLCA, and KIRP are the cancer types where PRKAG2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRKAG2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Female	All	−0.570	<.001	10	view →
BLCA	Male	III,IV	−2.324	<.001	9	view →
KIRP	Female	All	−0.871	<.001	8	view →
KIRC	Male	II,III,IV	−0.454	<.001	7	view →
LUSC	All	II,III,IV	−0.642	<.001	6	view →
BRCA	Female	All	−0.374	<.001	6	view →
COAD	All	All	−0.362	<.001	6	view →
KICH	All	All	+0.678	.002	5	view →
LIHC	All	II,III,IV	−0.646	<.001	5	view →
LUAD	Female	II,III,IV	−0.407	.001	5	view →
READ	All	II,III,IV	−1.049	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

PRKAG2–THCA

Open the THCA breakdown →